FDA recently expanded the emergency use authorization for the Pfizer COVID-19 vaccine to include adolescents 12 through 15 years of age.
The agency amended the original emergency use authorization...
United States Trade Representative Katherine Tai announced the Biden-Harris Administration’s support for waiving COVID-19 vaccine intellectual property in order to speed up vaccine distribution...
CVS Health recently announced that it began administering COVID-19 vaccines at workplace vaccination sites to increase access to vaccinations.
The vaccination increase comes on the heels of...
Gavi, the Vaccine Alliance, recently announced that it signed an advance purchase agreement with Moderna for 500 million doses of its mRNA COVID-19 vaccine.
The initial supply under the...
Moderna recently announced that it will increase global 2022 capacity for its COVID-19 vaccine to up to 3 billion doses, boosting production at its owned and partnered manufacturing facilities.
The...
FDA recently completed an inspection of Emergent BioSolutions, a proposed manufacturing facility for Johnson & Johnson’s COVID-19 vaccine.
The agency’s assessments reviewed the...
FDA and the CDC recently lifted the pause of the Johnson & Johnson COVID-19 vaccine in the US following a thorough safety review, including two meetings of the CDC’s Advisory Committee of...
Johnson & Johnson recently announced that the rollout of its COVID-19 vaccine will resume in Europe.
The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee...
Moderna recently announced Phase 1 data updates for its RSV vaccine candidate and new seven-month interim Phase 2 data regarding its cytomegalovirus (CMV) vaccine candidate.
Researchers stated...
Roche recently confirmed positive results from the Phase 3 trial assessing its COVID-19 antibody cocktail, which aims to reduce coronavirus infection among household contacts of individuals infected...
The CDC and FDA are reviewing data involving six reported cases of a severe and rare kind of blood clot in individuals who received the Johnson & Johnson (Janssen) COVID-19 vaccine.
This comes...
The New England Journal of Medicine (NEJM) recently released antibody persistence data six months following the second dose of Moderna’s COVID-19 vaccine, mRNA-1273.
As detected by three...
Many European countries, including Germany, France, Italy, and Spain recently suspended the use of AstraZeneca’s COVID-19 vaccine after experts found dangerous blood clots in some vaccine...
The Biden Administration recently appointed Johnson & Johnson to lead COVID-19 vaccine production at a Baltimore manufacturing plant that contaminated 15 million doses of the pharmaceutical...
FDA recently announced two revisions regarding the number of doses per vial available for Moderna’s COVID-19 vaccine, mRNA-1273.
The agency’s first revision clarifies the number of doses...
NIH recently announced that it has started a Phase 1 clinical trial of Moderna’s variant-specific COVID-19 vaccine candidate, mRNA-1273.351.
Researchers will evaluate the safety and...
Pfizer and BioNTech recently announced that its COVID-19 vaccine, BNT162b2, demonstrated 100 percent efficacy and robust antibody responses in adolescents with or without prior SARS-CoV-2...
A new CDC study used real-world evidence to find that mRNA COVID-19 vaccines are highly effective in preventing SARS-CoV-2 infections among healthcare personnel, first responders, and other essential...
Moderna recently announced that the first participants were dosed in the Phase 2/3 study of its COVID-19 vaccine candidate, mRNA-1273, in children six months to up to 12 years of age.
The study,...
AstraZeneca recently announced that its COVID-19 vaccine was 76 percent effective against the coronavirus and 100 percent effective at preventing severe disease and hospitalization in a Phase 3...